Basel-based startup Allegria has closed a USD 3.5 million seed financing round led by Forty51 Ventures to advance the research and development of its therapeutics for mast cell-mediated diseases. This news coincides with the appointment of co-founder Dr Maria van Dongen as the new CEO.
